Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jun 15;35(1):ivac143.
doi: 10.1093/icvts/ivac143.

Ruxolitinib withdrawal complicating emergency aortic root replacement

Malgorzata Maggie Szpytma  1 , Damian Gimpel  1 , Gareth Crouch  1 , Jayme S Bennetts  1   2
Affiliations
Case Reports

Ruxolitinib withdrawal complicating emergency aortic root replacement

Malgorzata Maggie Szpytma et al. Interact Cardiovasc Thorac Surg. .

Abstract

Ruxolitinib, a Janus kinase inhibitor, is associated with severe withdrawal phenomena. Adequate tapering is often underemphasized in surgical emergencies and can complicate the postoperative course. We present a case of acute ruxolitinib withdrawal in a gentleman undergoing emergency cardiac surgery.

Keywords: Aortic syndrome; Cardiac surgery; Ruxolitinib.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Preoperative computed tomography angiography (A) axial (B) coronal and (C) 3D reconstruction.
Figure 2:
Figure 2:
Postoperative trans-oesophageal echocardiogram of aortic valve and left ventricular outflow tract. Arrows depict clot abutting valve leaflets (A/B).
See this image and copyright information in PMC

References

    1. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM.. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 2017;77:521–46. - PMC - PubMed
    1. Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS. et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol 2020;11:1648. - PMC - PubMed
    1. Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M. et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Sci Adv 2018;4:eaat3834. - PMC - PubMed
    1. Beauverd Y, Samii K.. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol 2014;100:498–501. - PMC - PubMed
    1. Özkan M, Gündüz S, Gürsoy OM, Karakoyun S, Astarcıoğlu MA, Kalçık M. et al. Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: the ultra-slow PROMETEE trial. Am Heart J 2015;170:409–18. - PubMed

Publication types